Test whether carefully titrated D2-pathway modulation can normalize pathological autoreceptor signaling after alpha-synuclein pathology is established. The current debate supports this only as a mechanistic probe with direct electrophysiology and dopamine-release readouts, not yet as a strong therapeutic program.
Curated pathway from expert analysis
flowchart TD
A["SNCA Alpha-Synuclein<br/>Presynaptic Protein"]
B["SNCA Misfolding<br/>Environmental Stress"]
C["SNCA Oligomers<br/>Toxic Protofibrils"]
D["Mitochondrial Pore<br/>Membrane Disruption"]
E["Lewy Body Formation<br/>Cytoplasmic Inclusions"]
F["Dopaminergic Neuron<br/>Dysfunction/Death"]
G["Nigrostriatal Degeneration<br/>Motor Symptoms"]
H["SNCA A53T/A30P/E46K<br/>Familial PD Mutations"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"accelerates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for DRD2 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for DRD2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF a low-dose D2 dopamine receptor agonist (e.g., quinpirole 0.01-0.1 mg/kg, sc) is administered to rats with established alpha-synuclein pathology (≥8 weeks post-rAAV-αSyn injection in substantia nig | Restoration of regular, non-bursting firing pattern in ≥70% of recorded dopaminergic neurons, with firing rate returning to within 1 SD of age-matched control v | — no observation — | pending | 0.35 |
| IF a Gi/o-biased D2 autoreceptor positive allosteric modulator (PAM) is administered chronically (once daily, 14 days) to mice with established alpha-synuclein pathology (≥6 months post Thy1-αSyn tran | Striatal dopamine release amplitude increasing by ≥40% toward WT baseline, with full restoration of the D2 agonist (quinpirole 0.3 mg/kg)-mediated % inhibition | — no observation — | pending | 0.28 |